How to Effectively Manage Life With Central Sleep Apnea(CSA)?
The first-line ventilatory treatment for central sleep apnea (CSA) depends on the underlying etiology, clinical context, and left ventricular ejection fraction (LVEF), particularly in patients with heart failure. For most CSA patients, continuous positive airway pressure (CPAP) is recommended as the first-line therapy, especially in those with CSA associated with chronic heart failure (CHF). CPAP stabilizes the upper airway, reduces ventilatory overshoot after apneic events, and improves oxygenation and pulmonary congestion. The 2022 Brazilian Sleep Association (BSA) Guideline supports CPAP as a first-line option for CSA in CHF, with Class A evidence[1]. CPAP has been shown to reduce the apnea-hypopnea index (AHI) and improve sleep architecture, although its impact on long-term cardiovascular outcomes remains neutral.
In patients who fail or cannot tolerate CPAP, adaptive servo-ventilation (ASV) is a second-line option. ASV dynamically adjusts pressure support based on real-time breathing patterns, effectively suppressing central apneas and stabilizing ventilation. However, its use in heart failure is highly restricted due to safety concerns from the SERVE-HF trial, which demonstrated a 28% increase in all-cause mortality and 34% increase in cardiovascular mortality in HFrEF patients (LVEF ≤45%) treated with ASV[2]. As a result, ASV is contraindicated in symptomatic HFrEF patients with LVEF ≤45% according to major guidelines, including the 2023 National Heart Failure Guideline[3] and the 2023 JCS Guideline on Sleep Disorders in Cardiovascular Disease[4]. Subgroup analyses suggest the risk may be concentrated in patients with LVEF <30%, while those with LVEF >36% may not face increased mortality[4]. The 2025 JCS/JHFS Guideline notes that ASV may be considered cautiously in patients with LVEF <45% and predominant CSA only if CPAP is ineffective or not tolerated, and only after careful risk-benefit assessment[5]. In non-HFrEF populations or those with idiopathic CSA, Cheyne-Stokes respiration without severe systolic dysfunction, or opioid-induced CSA, ASV is considered safe and effective. Transvenous phrenic nerve stimulation (TPNS) is emerging as an alternative for select patients with persistent CSA despite optimal medical and PAP therapy, showing improvements in quality of life and symptom burden without increased mortality risk[6]. In summary, CPAP is the first-line ventilatory therapy for CSA, particularly in heart failure. ASV is not recommended in HFrEF with LVEF ≤45% due to mortality risk but may be considered in milder systolic dysfunction or non-cardiac CSA under expert supervision. Treatment decisions should be individualized and made within a multidisciplinary. I suggest you further explore the safety and efficacy of adaptive servo-ventilation in patients with varying degrees of left ventricular dysfunction, particularly referencing recent cardiovascular outcome studies and guideline updates.
References:
1. Practice recommendations for the role of physiotherapy in the management of sleep disorders: the 2022 Brazilian Sleep Association Guidelines
2. Effect of adaptive servo-ventilation for central sleep apnoea in systolic heart failure on muscle sympathetic nerve activity: a SERVE-HF randomised ancillary study
3. China National Heart Failure Guideline 2023
4. JCS 2023 Guideline on Diagnosis and Treatment of Sleep Disordered Breathing in Cardiovascular Disease
5. JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
6. Treating central sleep apnoea in heart failure: is positive airway pressure and adaptive servo-ventilation in particular the gold standard?
This content is intended for educational purposes only. It should not be relied upon as a substitute for professional medical advice, diagnosis, or treatment.
